Lessons learned and applied: What the 20th century vaccine experience can teach us about vaccines in the 21st century

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 5, 2012, Pages 560-568

  Hebert, Corey Joseph ^a,b   Hall, Corey M ^a   Odoms, La Nyia J ^a  

^a BHTV ^*

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Childhood vaccinations; Haemophilus influenzae; High risk populations; Immunization; Infants; Meningococcal disease; Neisseria meningitidis; Pediatrics; Streptococcus pneumoniae

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCAL CONJUGATE VACCINE 7; PNEUMOCOCCAL POLYSACCHARIDE VACCINE 14; PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

CHILD CARE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIPHTHERIA; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; HAEMOPHILUS INFECTION; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MEASLES; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; MUMPS; PERTUSSIS; PNEUMOCOCCAL INFECTION; PUBLIC HEALTH SERVICE; REVIEW; RUBELLA; TETANUS; TREATMENT DURATION; UNITED STATES; VACCINATION;

DRUG UTILIZATION; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; UNITED STATES; VACCINATION; VACCINES;

EID: 84863636557     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19204     Document Type: Review

References (68)

1. Centers for Disease Control and Prevention (CDC). Ten great public health achievements-United States, 2001-2010. MMWR Morb Mortal Wkly Rep 2011; 60:619-23; PMID:21597455
2. Centers for Disease Control and Prevention (CDC). Ten great public health achievements-worldwide, 2001-2010. MMWR Morb Mortal Wkly Rep 2011; 60:814-8; PMID:21697806
3. Centers for Disease Control and Prevention (CDC). Impact of vaccines universally recommended for children-United States, 1990-1998. MMWR Morb Mortal Wkly Rep 1999; 48:243-8; PMID:10220251
4. Offit PA. Vaccinated: One Man's Quest to Defeat the World's Deadliest Diseases. Washington, DC: Smithsonian, 2007.
5. Roush SW, Murphy TV & Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007; 298:2155-63; PMID:18000199; http://dx.doi.org/10.1001/jama.298.18.2155
6. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR-9):1-35; PMID: 11055835
7. Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases: United States, 2009. MMWR Morb Mortal Wkly Rep 2011; 58:1-100; PMID:21566560
8. Centers for Disease Control and Prevention. Recommended Immunization Schedule for Persons Aged 0 Through 6 Years - United States 2011. http://www.cdc.gov/vaccines/recs/schedules/downloads/child/0-6yrs-schedule-pr. pdf. Accessed September 2, 2011.
9. Guyer B, Freedman MA, Strobino DM, Sondik EJ. Annual summary of vital statistics: trends in the health of Americans during the 20th century. Pediatrics 2000; 106:1307-17; PMID:11099582; http://dx.doi.org/10.1542/peds.106. 6.1307
10. Zhou F. Updated economic evaluation of the routine childhood immunization schedule in the United States. Presented at the 45th National Immunization Conference. Washington, DC; March 28-31, 2011.
11. GAVI Alliance web site. http://www.gavialliance.org/about/. Accessed July 19, 2011.
12. Bloom DE. The value of vaccination. In Curtis N et al, eds. Hot Topics in Infection and Immunity in Children VII. Advances in Experimental Medicine and Biology, 697. New York, NY: Springer Science+Business Media, LLC, 2011; DOI: 10.1007/978-1-4419-7185-2-1.
13. Offit PA. Autism's False Prophets. Bad Science, Risky Medicine, and the Search for a Cure. New York, NY: Columbia University Press, 2008.
14. Offit PA, Quarles J, Gerber MA, et al. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics 2002; 109(1):124-9; PMID: 11773551; DOI: 10.1542/peds.109.1.124. 2002.
15. Choi YH, Gay N, Fraser G, Ramsay M. The potential for measles transmission in England. BMC Public Health 2008; 8:338; PMID:18822142; http://dx.doi.org/10.1186/1471-2458-8-338
16. Gust DA, Darling N, Kennedy A, Schwartz B. Parents with doubts about vaccines: which vaccines and reasons why. Pediatrics 2008; 122:718-25; PMID:18829793; http://dx.doi.org/10.1542/peds.2007-0538
17. Dempsey AF, Schaffer S, Singer D, Butchart A, Davis M, Freed GL. Alternative vaccination schedule preferences among parents of young children. Pediatrics 2011; 128:848-56; PMID:21969290; http://dx.doi.org/10.1542/peds.2011- 0400
18. Jansen VA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ, Rhodes CJ. Measles outbreaks in a population with declining vaccine uptake. Science 2003; 301:804; PMID:12907792; http://dx.doi.org/10.1126/science.1086726
19. Atkinson WL, Pickering LK, Watson JC, Peter G. General immunization practices. In: Plotkin SA and Orenstein WA. Vaccines. 4th edition. Philadelphia, PA: WB Saunders, 2004:p91.
20. National Center for Immunization and Respiratory Diseases. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-64; PMID:21293327
21. Centers for Disease Control and Prevention. CDC Health Information for International Travel 2012. New York, NY: Oxford University Press; 2012.
22. Jaspan HB, Lawn SD, Safrit JT, Bekker LG. The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. AIDS 2006; 20:483-94; PMID:16470112; http://dx.doi.org/10.1097/01. aids.0000210602.40267.60
23. Velilla PA, Rugeles MT, Chougnet CA. Defective antigen-presenting cell function in human neonates. Clin Immunol 2006; 121:251-9; PMID:17010668; http://dx.doi.org/10.1016/j.clim.2006.08.010
24. Zinkernagel RM. Maternal antibodies, childhood infections, and autoimmune diseases. N Engl J Med 2001; 345:1331-5; PMID:11794153; http://dx.doi.org/10. 1056/NEJMra012493
25. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed. Washington DC: Public Health Foundation, 2011.
26. Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among children aged 19-35 months-United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1157-63; PMID: 21881546
27. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005; 24 (Suppl):S58-61; PMID:15876927; http://dx.doi.org/10.1097/01.inf. 0000160914.59160.41
28. Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, Roord J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011; 11:557-70; PMID:21600850; http://dx.doi.org/10.1016/S1473- 3099(11)70007-X
29. Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years-United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1117-23; PMID:21866084
30. Bloch AB, Orenstein WA, Stetler HC, Wassilak SG, Amler RW, Bart KJ, et al. Health impact of measles vaccination in the United States. Pediatrics 1985; 76:524-32; PMID:3931045
31. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351:637-41; PMID:9500320; http://dx.doi.org/10.1016/S0140-6736(97)11096-0
32. The Lancet Editors. Retraction-Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 2010; 375:45.
33. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002. J Pediatr 2003; 143(Suppl):S163-87; PMID: 14657805; http://dx.doi.org/10.1067/S0022-3476(03)00576-6
34. Wenger JD. Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatr Infect Dis J 1998; 17(Suppl):S132-6; PMID:9781746; http://dx.doi.org/10.1097/00006454-199809001-00008
35. Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993; 269:221-6; PMID: 8417239; http://dx.doi.org/10.1001/ jama.1993.03500020055031
36. Centers for Disease Control and Prevention (CDC). Progress toward eliminating Haemophilus influenzae type b disease among infants and children-United States, 1987-1997. MMWR Morb Mortal Wkly Rep 1998; 47:993-8; PMID:9843325
37. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al & Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41; PMID:19947881; http://dx.doi.org/10.1086/ 648593
38. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, et al & Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285:1729-35; PMID: 11277827; http://dx.doi.org/10.1001/jama.285. 13.1729
39. World Health Organization. WHO position paper on Meningococcal vaccines. Wkly Epidemiol Rec 2002; 77:329-40.
40. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91; PMID:20001736; http://dx.doi.org/10.1086/649209
41. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 2006; 24:4692-700; PMID: 16621189; http://dx.doi.org/10.1016/j.vaccine.2006.03.034
42. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27(Suppl 2):B51-63; PMID:19477562; http://dx.doi.org/10. 1016/j.vaccine.2009.04.063
43. Centers for Disease Control and Prevention. Vaccines and Preventable Diseases. Factsheet: Meningococcal Disease and Meningococcal Vaccines (August 26, 2009). http://www.cdc.gov/vaccines/vpd-vac/mening/vac-mening-fs.htm. Accessed June 26, 2011.
44. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88; PMID:11333996; http://dx.doi.org/10.1056/NEJM200105033441807
45. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011; 60:72-6; PMID: 21270745
46. Sanofi Pasteur Inc. Menactra Prescribing Information. Swiftwater, PA. 2011.
47. Novartis Vaccines and Diagnostics. MENVEO Prescribing Information. March 2011.
48. National Center for Immunization and Respiratory Diseases. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-64; PMID:21293327
49. Lingappa JR, Rosenstein N, Zell ER, Shutt KA, Schuchat A, Perkins BA & Active Bacterial Core surveillance (ABCs) team. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine 2001; 19:4566-75; PMID:11483285; http://dx.doi.org/10.1016/S0264-410X(01)00209-2
50. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853-61; PMID:21075057; http://dx.doi.org/10.1016/S1473-3099(10)70251-6
51. Centers for Disease Control and Prevention (CDC). Vaccination coverage among adolescents aged 13-17 years - United States, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:1100-3; PMID:18846032
52. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7; PMID:15276396; http://dx.doi.org/10.1016/S0140-6736(04) 16725-1
53. Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-43; PMID: 18271745; http://dx.doi.org/10.1086/527401
54. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326:365-6; PMID:12586669; http://dx.doi.org/10.1136/bmj.326. 7385.365
55. De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J 2011; 30:566-9; PMID:21326136; http://dx.doi.org/10.1097/INF.0b013e31820e8638
56. De Wals P, Deceuninck G, Boulianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004; 292:2491-4; PMID:15562128; http://dx.doi.org/10.1001/jama.292.20.2491
57. Plotkin SA. Vaccines: past, present and future. Nat Med 2005; 11(Suppl):S5-11; PMID:15812490; http://dx.doi.org/10.1038/nm1209
58. Plotkin SA, Plotkin SL. The development of vaccines: how the past led to the future. Nat Rev Microbiol 2011; 9:889-93; PMID:21963800; http://dx.doi.org/10.1038/nrmicro2668
59. Maldonado YA, Lawrence EC, DeHovitz R, Hartzell H, Albrecht P. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics 1995; 96:447-50; PMID:7651776
60. Manikkavasagan G, Ramsay M. Protecting infants against measles in England and Wales: a review. Arch Dis Child 2009; 94:681-5; PMID:19457878; http://dx.doi.org/10.1136/adc.2008.149880
61. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998; 280:527-32; PMID:9707142; http://dx.doi.org/10.1001/jama.280.6.527
62. Gans HA, Yasukawa LL, Alderson A, Rinki M, DeHovitz R, Beeler J, et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 2004; 190:83-90; PMID:15195246; http://dx.doi.org/10.1086/421032
63. WHO Consultative Group. The relation between acute persisting spinal paralysis and poliomyelitis vaccine-results of a ten-year enquiry. Bull World Health Organ 1982; 60:231-42; PMID:6980734
64. Rosenthal S, Chen R, Hadler S. The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med 1996; 150:457-60; PMID:8620224; http://dx.doi.org/10.1001/archpedi. 1996.02170300011001
65. Offit PA. Deadly Choices: How the Anti-Vaccine Movement Threatens Us All. New York, NY: Basic Books, 2011.
66. Centers for Disease Control and Prevention. State vaccination requirements. http://www.cdc.gov/vaccines/vac-gen/laws/state-reqs.htm. Accessed December 16, 2011.
67. Stobbe MAP. IMPACT: More kids skip school shots in 8 states. Associated Press. November 28, 2011. http://news.yahoo.com/ap-impact-more-kids-skip-school- shots-8-085128437.html. Accessed December 16, 2011.
68. Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis 2004; 8:188-94; PMID:15874862; http://dx.doi.org/10.1097/00128360- 200407000-00005